Trial Profile
A Randomized, Single-center, Parallel-group, Prospective Trial of Neuroprotective Effect of Liraglutide for Treatment of Diabetic Polyneuropathy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- 03 Feb 2021 Status changed from recruiting to discontinued.
- 22 Apr 2020 Planned End Date changed from 28 Feb 2021 to 28 Feb 2023.
- 28 May 2016 New trial record